Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Nyiregyhaza – page 6

164 clinical trials in Nyiregyhaza, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Nyiregyhaza at a glance
164
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

164 trials in Nyiregyhaza

Open in trial search

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Contraception

Not recruiting

Study on the Effectiveness and Safety of Levonorgestrel Vaginal Delivery System vs. Desogestrel Tablets for Preventing Pregnancy in Women

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · Healthy volunteers
  • Substances:Desogestrel
  • Sponsor:Chemo Research S.L.

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Nyiregyhaza

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative and HR-positive/HER2-negative variants. Research extends to bladder cancer and lymphoma treatments.

  • Advanced metastatic breast cancer therapies
  • Large B-cell lymphoma treatments
  • Bladder cancer immunotherapy combinations

Several studies are evaluating novel drug combinations and comparing their efficacy to standard treatments.

02 Cardiovascular & Metabolic Diseases

Comprehensive research into heart failure prevention and treatment of cardiovascular disease. Studies include innovative approaches for managing chronic conditions.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Chronic kidney disease management

Trials are investigating new therapeutic combinations to improve patient outcomes in cardiovascular conditions.

03 Respiratory & Inflammatory Conditions

Studies addressing chronic rhinosinusitis and respiratory infections, with particular focus on nasal polyps treatment and viral lung infections.

  • Nasal polyps treatment innovations
  • Respiratory syncytial virus prevention
  • Asthma management strategies

Research includes both preventive measures and therapeutic interventions for respiratory conditions.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.